Updated: GSK nabs priority review on RSV vaccine, kicks off showdown with Pfizer — while 'setting the bar high' on R&D

GSK appears to have beaten Pfizer in getting a BLA for its RSV vaccine in front of the FDA, securing priority review for the use …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Up­dat­ed: GSK nabs pri­or­i­ty re­view on RSV vac­cine, kicks off show­down with Pfiz­er — while 'set­ting the bar high' on R&D